+60

# adifyline<sup>®</sup>

# Perfect curves against gravity



## Stimulates adipogenesis

(  )
$I \times (-\Lambda)I$
101
facial redefining

### Description

Hexapeptide that increases fatty tissue volume in specific areas improving facial appearance and providing attractive body curves. adifyline<sup>®</sup> *peptide* stimulates peroxisome proliferatoractivated receptor gamma coactivator 1α (PGC-1α) expression, enhancing adipogenesis rate. This leads to a higher lipid accumulation and volume growth in the desired areas like breast and cheeks.

### **Appearance**

Transparent solution containing 0.05% Acetyl Hexapeptide-38.

### INCI

Butylene Glycol, Water (Aqua), Acetyl Hexapeptide-38.

### **Properties**

A volume increase in the adipose tissue in the desired areas results in an attractive appearance. adifyline<sup>®</sup> peptide stimulates PGC-1α expression, raising adipogenesis rate and lipid accumulation.

### **Applications**

adifyline<sup>®</sup> peptide can be incorporated into facial redefining or breast firming formulations, and in any product where a replenishing effect is desired.

### Increases cheek volume

# Provides a curvy silhouette

### Science

When aging, skin gets thinner, loses firmness and gravity pulls it downwards leading to undesired and visible changes in the face and body. Furthermore, adipose tissue, which is mostly found beneath the skin and acting as a supporting tissue, gets redistributed and decreases in areas like cheeks, facial oval, breasts or hands. Nowadays, the relevance of perfect curves in the face and body make people look for efficient and non-aggressive ways of increasing tissue volume.

PGC-1 $\alpha$  is a transcriptional coactivator that, interacting with the peroxisome proliferator-activated receptor PPAR $\gamma$ , modulates adipogenesis rate.

adifyline<sup>®</sup> peptide increases local volume improving facial appearance and providing a curvy silhouette, by promoting PGC-1 $\alpha$  expression and lipid accumulation in the adipose tissue.

Dosage 2%

Solubility

Soluble in water.








# In vitro efficacy

### **1. EFFECT ON PGC-1α EXPRESSION**

Human preadipocytes were incubated in a growth medium and differentiated with preadipocyte differentiation medium (PDM-2) in presence of adifyline<sup>®</sup> peptide. After 10 days, cells were lysed, RNA was extracted and reverse transcription was carried out. The resulting cDNA was analyzed by quantitative RT-PCR.




adifyline

peptide

adifyline<sup>®</sup> *peptide* promoted PGC-1α expression by more than 61%

### 2. EFFECT ON LIPID ACCUMULATION

adifyline<sup>®</sup> peptide was added to human preadipocytes during their differentiation with PDM-2. After 10 days, levels of intracellular lipid droplets were measured by fluorescence.



Lipid accumulation is higher in cells treated with adifyline® *peptide* 


# In vivo efficacy

### **1. FACIAL VOLUME INCREASE**

A group of 22 female volunteers (aged between 50 and 60) applied a cream containing 2% adifyline<sup>®</sup> peptide solution on the cheeks twice a day for 14 days.

The cheek volume was analyzed by Fringe Projection at the end of the study. This technique allows the direct acquisition of the morphology of the studied area in 3D, being able to obtain the volume in mm<sup>3</sup>.






Cheek volume increased by 12% after 14 days with adifyline® *peptide* 

### 2. BREAST VOLUME INCREASE

adifyline<sup>®</sup> peptide was tested on a group of 22 women aged 25 to 40 with a bra cup size between 80 and 90. A cream containing 2% adifyline<sup>®</sup> peptide solution was applied on a breast and the placebo on the other, twice a day for 56 days.

Measurements of breast volume were taken at day 14, 28 and 56 using the FOITS technique.



0 days 56 days

The trademarks referenced in this brochure are owned by The Lubrizol Corporation or its affiliates. While the information contained herein is believed to be reliable, there are no representations, guarantees, or warranties of any kind made as to its accuracy, suitability for particular applications, how the product(s) will perform in combination with other substance or in the User's process or the results obtained. All expressed and implied warranties are disclaimed. Lubrizol and its affiliates MAKE NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES or MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. The User is solely responsible for ensuring that products marked to consumers comply with all relevant laws and regulations and assumes all risk and liability of any use or handling of any materials. User agrees to indemnify and hold harmless Lubrizol and its affiliates for any and all actions arising from User's use of any information including claims in this publication, including, but not limited to, use in advertising and finished product label claims, and not present this publication as evidence of finished product claim substantiation to any regulatory authority. It is the User's sole responsibility to determine if three are any issues relating to patent this publication as epylied information. Nothing contained herein is to be considered as permission, recommendation, nor as an inducement to practice any patented invention without permission of the patent owner.

Isaac Peral 17 Pol. Industrial Camí Ral - 08850 Gavà (Barcelona) Spain - Tel +34 93 638 80 00 - commercial@lipotec.com

improved breast volume

by 30-fold compared to placebo after 56 days

adifyline® peptide

Ed. 16B © 2013-2016 The Lubrizol Corporation. All Rights Reserved.